As the TIGIT class gets closer to finally seeing clinical success, Bristol Myers Squibb is trimming one of its candidates.

随着TIGIT课程越来越接近最终看到临床成功，百时美施贵宝正在修剪其中一位候选人。

The company disclosed development of a phase 2 anti-TIGIT is ending as part of its annual R&D day on Thursday. BMS is also halting work on a phase 2 nonalcoholic steatohepatitis (NASH) candidate licensed in 2016 from Nitto Denko Corporation and a handful of other phase 1 assets.

该公司披露，第二阶段反TIGIT的开发将于周四结束，作为其年度研发日的一部分。BMS还停止了2016年从Nitto Denko Corporation和其他一些1期资产获得许可的2期非酒精性脂肪性肝炎（NASH）候选人的工作。

“We regularly evaluate our pipeline to best prioritize resources where we see the potential for transformational effects on patients’ lives,” a spokesperson said in a statement.

一位发言人在一份声明中说：“我们定期评估我们的管道，以便最好地优先考虑资源，我们可以看到对患者生活产生变革影响的可能性。

BMS terminated a phase 2 study of the anti-TIGIT in solid tumors in late January due to “safety reasons, adverse change in the risk/benefit,” according to the clinical trial record. The record for a phase 1/2 multiple myeloma trial, sponsored by the Multiple Myeloma Research Consortium, was last updated in July to indicate it was active and recruitment had been completed..

根据临床试验记录，由于“安全原因，风险/收益的不利变化”，BMS于1月下旬终止了实体瘤抗TIGIT的2期研究。由多发性骨髓瘤研究联盟赞助的1/2期多发性骨髓瘤试验记录最近于7月更新，表明其活跃且招募已完成。。

The decision comes as the class is potentially on the precipice of a bit of momentum, led by Roche’s tiragolumab. Data released last year found that the asset in combination with Tecentriq did not improve progression-free survival in first-line non-small cell lung cancer patients, throwing into question the potential of the class that had garnered investments from numerous Big Pharmas.

这个决定是因为该班可能处于由罗氏的tiragolumab领导的一点势头的精确性。去年发布的数据发现，这项资产与Tecentriq联合使用并不能改善一线非小细胞肺癌患者的无进展生存期，这使人们质疑该班从众多大型制药公司获得投资的潜力。

But an inadvertent data drop last month showed that treated patients did live longer compared to patients on just Tecentriq, though not by a statistically significant amount. Nonetheless, Roche’s shared jump on the news..

但是上个月无意中的数据下降表明，与仅使用Tecentriq的患者相比，接受治疗的患者的寿命确实更长，尽管没有统计学意义。尽管如此，罗氏在新闻上的共同跳跃。。

BMS is evidently pushing all of its TIGIT chips toward a bispecific candidate licensed from Agenus in May 2021 for $200 million upfront. Agenus also stands to earn $1.36 billion in milestone payments. The bispecific is in a phase 1 trial in patients with solid tumors as both a monotherapy and in combination with a PD-1 inhibitor..

BMS显然将其所有TIGIT芯片推向了2021年5月从Agenus获得许可的双特异性候选药物，并以2亿美元的价格提供前期资金。Agenus的里程碑付款也将获得13.6亿美元。双特异性是作为单一疗法和与PD-1抑制剂组合的实体瘤患者的1期临床试验。。

The NASH med was a siRNA asset targeting heat shock protein 47 that cost BMS $100 million to license in 2016. A phase 2 trial testing BMS-986263 in patients with advanced hepatic fibrosis that had been cured of hepatitis C wrapped up in February 2022. Data published in April last year showed that the most significant improvement in fibrosis was in patients at the 90-mg dose level, the highest in the trial, and that all adverse events were mild to moderate..

NASH med是一种针对热休克蛋白47的siRNA资产，2016年许可证费用为1亿美元。在2022年2月包裹的已治愈丙型肝炎的晚期肝纤维化患者中进行了BMS-986263的2期临床试验。去年4月公布的数据显示，纤维化最显着的改善是90 mg剂量水平的患者，试验中最高，所有不良事件均为轻度至中度。。

The early-stage cuts include a cancer molecule aimed at an undisclosed target, a CD47 and CD20-targeting lymphoma med, a leukemia treatment and a RIPK1 inhibitor.

早期切割包括针对未公开靶标的癌症分子，靶向淋巴瘤med的CD47和CD20，白血病治疗和RIPK1抑制剂。